axelroark

IBB Breakdown After Back Test

Short
NASDAQ:IBB   iShares Biotechnology ETF
IBB is showing weakness, having broken through a key support area and then failed to recover in day 1 of the back test. Expect to see re-test of 98'ish support, with failure leading to a re-test of December 2018 lows, and perhaps much lower. Bang for buck isn't great here, so we aren't taking the trade, but risk/reward is very good on this move.

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.